Summary of findings table for secondary outcomes: number of surfactant doses required
| Surfactant: doses (n) | Threshold 60% | Threshold 30% | Threshold 50% | Threshold 40% | ||||
| Studies: 13 Participants: 5142 | ||||||||
| Prophylaxis: 1107 per 1000 (110.7 per 100 participants) | RaR 0.26 (0.21 to 0.32) Network estimate | 815 fewer per 1000 (870 fewer to 750 fewer) | RaR 0.51 (0.46 to 0.56) Network estimate | 546 fewer per 1000 (602 fewer to 484 fewer) | RaR 0.65 (0.58 to 0.73) Network estimate | 384 fewer per 1000 (463 fewer to 297 fewer) | RaR 0.71 (0.63 to 0.81) Network estimate | 316 fewer per 1000 (406 fewer to 215 fewer) |
| Rank: 5 (5–5) | Rank: 1 (1–1) | Rank: 2 (2–2) | Rank: 3 (3–4) | Rank: 4 (3–4) | ||||
| Quality of evidence: ⊕⊕◯◯ Low *† | Based on 334 participants (3 RCTs) | Based on 881 participants (3 RCTs) | Based on 742 participants (2 RCTs) | Based on 511 participants (5 RCTs) | ||||
All results are reported as OR with 95% credible intervals.
*The trials were all had some concerns or were at high risk of bias.
†There was significant heterogeneity.
RaR, rate ratio; RCT, randomised controlled trial.